▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Dave Williamson

XMFGreenwave4

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Recent Articles by Dave Williamson

Dec 14, 2012 by Dave Williamson and Brenton Flynn

1 Buyout Bolstering Big Biotech

Gilead is renowned for its antiviral drugs, but who knew about its interesting oncology pipeline?

Dec 13, 2012 by Dave Williamson and Brenton Flynn

Is Eli Lilly on a Fruitless Quest?

This company's Alzheimer's disease drug may never be approved. Should Eli Lilly keep pushing?

Dec 13, 2012 by Dave Williamson and Max Macaluso

The Best of 2012 #10: Schiff Nutrition

Airborne maker Schiff Nutrition gives you 167% of your daily vitamin C per tablet, and has given investors 292% growth this year. That makes them #10 on our list of the very best health-care stocks of 2012.

Dec 13, 2012 by Dave Williamson and Max Macaluso

The Best of 2012 #9: Hemispherx BioPharma

Hemispherx is up 295% year to date over excitement about its resubmission of its chronic fatigue syndrome drug, which lands the company at #9 on our list of the best healthcare performers of 2012.

Dec 13, 2012 by Dave Williamson and Max Macaluso

The Best of 2012 #6: Celsion

Celsion's platform targeting cancer cells more specifically has the company up 341% for the year, making it #6 on our list of the very best in health-care stocks of 2012.

Dec 13, 2012 by Dave Williamson and Max Macaluso

The Best of 2012 #7: Sunesis

After announcing an expansion of P3 trials for its acute myeloid leukemia drug, Sunesis Pharmaceuticals shot to new heights, up 325% for the year. That puts it at #7 on our list of the very best stocks in healthcare for 2012.

Dec 13, 2012 by Dave Williamson and Max Macaluso

The Best of 2012 #8: TearLab

A leader in tear testing for biomarker analysis, TearLab is up 296% this year, making it #8 on our list of the best stocks in healthcare for 2012.

Dec 11, 2012 by Dave Williamson

Are the Shorts Wrong About Questcor?

Questcor is the second most shorted company in the entire health-care sector.

Dec 11, 2012 by Dave Williamson

Are the Shorts Wrong About MAKO?

MAKO Surgical is the sixth most short-sold health-care stock on the market.

Dec 11, 2012 by Dave Williamson and Brenton Flynn

Are the Shorts Wrong About Dendreon?

Are all of Dendreon's short-sellers about to come up short themselves?

Dec 10, 2012 by Dave Williamson

This FDA Approval Changes Nothing

This positive step forward was one everyone saw coming.

Dec 10, 2012 by Dave Williamson

Acura Investors: Why Shares Popped 70%

Another abuse-resistant drug for Acura sees a huge jump in share price.

Dec 10, 2012 by Dave Williamson and Max Macaluso

The Best of 2012: Endocyte

Up 149% for the year, Endocyte has been a cash cow for investors, which lands it at #21 on our list of the very best healthcare stocks of 2012.

Dec 10, 2012 by Dave Williamson and Max Macaluso

The Best of 2012: AMN Healthcare Services

Up 147% this year, AMN Healthcare Services falls at #22 on our list of the top 25 healthcare stocks that have been good to investors this year.

Dec 10, 2012 by Dave Williamson and Max Macaluso

The Best of 2012: Dyax

Up 140% this year, it's been an incredible year for Dyax investors, which landed the company at #23 on our list of the very best healthcare stocks of 2012.

Dec 10, 2012 by Dave Williamson and Max Macaluso

The Best of 2012: GenMark Diagnostics

GenMark's increase of 140% this year has left them at #24 on our list of the top 25 healthcare stocks of 2012.

Dec 10, 2012 by Dave Williamson and Max Macaluso

The Best of 2012: Insmed

Now we begin our look at the top gaining 25 stocks in the healthcare space with #25, up 134% this year, Insmed.

Dec 7, 2012 by Dave Williamson and Max Macaluso

Sarepta Updates its Potential Blockbuster

Surprisingly, Sarepta got a slight downturn from the markets after good results from its 62-week look at its groundbreaking new drug.

Dec 7, 2012 by Dave Williamson and Max Macaluso

Amarin's Wall Street Beating: Will It Recover?

Amarin sank like a stone today, down 20%, after its surprise after-hours decision.

Dec 6, 2012 by Dave Williamson

Why Amarin Is Tanking After Hours

What happened to the buyout?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services